The study aims to reveal new insights into the impact of Tempol on specific, both known and unknown, signaling pathways in chronic kidney disease (CKD), with a focus on the regulation of NF-κB and TGF-β1/Smad3 pathways. Here, SMAD3 is linked to chronic kidney disease.